5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 9.48▲ | 9.43▲ | 9.40▲ | 9.17▲ | 8.20▲ |
MA10 | 9.44▲ | 9.30▲ | 9.27▲ | 8.88▲ | 7.71▲ |
MA20 | 9.29▲ | 9.19▲ | 9.15▲ | 8.15▲ | 8.07▲ |
MA50 | 9.12▲ | 9.04▲ | 8.83▲ | 7.60▲ | N/A |
MA100 | 9.00▲ | 8.51▲ | 8.12▲ | 8.03▲ | N/A |
MA200 | 8.39▲ | 7.83▲ | 7.69▲ | N/A | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.018▲ | 0.024▲ | 0.020▲ | 0.141▲ | 0.110▲ |
RSI | 68.428▲ | 67.451▲ | 67.015▲ | 70.526▲ | 58.248▲ |
STOCH | 97.656▲ | 97.245▲ | 92.036▲ | 85.611▲ | 64.314 |
WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -3.461▲ | -27.197 |
CCI | 81.211 | 125.519▲ | 132.819▲ | 108.106▲ | 133.999▲ |
Wednesday, April 30, 2025 01:00 AM
CHICAGO and FORT WORTH, Texas, April 30, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 9.10 | 9.595 | 9.07 | 9.50 | 39,700 |
30/04/25 | 8.88 | 9.46 | 8.88 | 9.20 | 25,209 |
29/04/25 | 9.00 | 9.195 | 8.82 | 9.17 | 32,769 |
28/04/25 | 8.975 | 9.115 | 8.90 | 9.05 | 23,228 |
25/04/25 | 9.00 | 9.00 | 8.54 | 8.95 | 129,997 |
24/04/25 | 8.82 | 9.12 | 8.68 | 9.04 | 48,000 |
23/04/25 | 8.52 | 9.40 | 8.52 | 9.00 | 96,475 |
22/04/25 | 8.37 | 8.74 | 7.995 | 8.52 | 290,300 |
21/04/25 | 8.00 | 8.40 | 7.59 | 8.37 | 79,500 |
17/04/25 | 8.07 | 8.23 | 7.92 | 8.00 | 52,000 |
|
|
||||
|
|
||||
|
|